He is an international leader in Stroke clinical trials and brain imaging and has translated much of his research into clinical practice change. He has published in all major neurology specialty journals as well as the highest impact general clinical journals, despite heavy clinical and administrative workloads. He is recognised by his peers nationally and internationally as one of the leading mid-career clinician neuroscientists in the world, evidenced by >300 articles in peer reviewed journals (h index 72), and >100 speaking invitations and session chairs at international conferences and >100 at national meetings. He has been the Chair of Organising Committees for >20 National and International Stroke Conferences. Professor Parsons has been an immediate past president of the Stroke Society of Australasia and has chaired the Australasian Stroke Trials Network. He has attracted over $35m to support his research program during the past five years and is currently leading two major NHMRC-funded clinical phase III randomised trials of tenecteplase across 50 centres internationally (Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation, TASTE; and Extending the time window for Tenecteplase by Effective Reperfusion of peNumbrAL tissue in patients with Large Vessel Occlusion, ETERNAL). He is also a CI on an NHMRC Program Grant “Saving Brain and changing practice in Stroke” for $13.7 million dollars. This Grant was ranked number 1 of all Program Grants for 2017.